Court Report -- January 19, 2014

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Biosuccess Biotech Co. Ltd. v. Rich Pharmaceuticals Inc. et al.
2:14-cv-00310; filed January 14, 2014 in the Central District of California

• Plaintiff:  Biosuccess Biotech Co. Ltd.
• Defendants:  Rich Pharmaceuticals Inc.; Imagic LLC; Richard L Chang Holdings LLC; Ben Chang; Does 1 through 10 inclusive

Infringement of U.S. Patent. No. 6,063,814 ("Phorbol Esters as Anti-Neoplastic and White Blood Cell Elevating Agents," issued May 21, 2000) based on defendants use of PD-616 and/or TPA for the treatment of victims of leukemia and stroke.  Also, various claims sounding in state law, including misappropriation of trade secrets, etc.  View the complaint here.

Pegasus Laboratories, Inc. v. Lowlite Investments, Inc.
6:14-cv-00051; filed January 10, 2014 in the Middle District of Florida

• Plaintiff:  Pegasus Laboratories, Inc.
• Defendant:  Lowlite Investments, Inc. d/b/a Olympia Compounding Pharmacy

Infringement of U.S. Patent Nos. 5,747,476 ("Treatment of Equine Protozoal Myeloencephalitis," issued May 5, 1998), 6,255,308 (same title, issued July 3, 2001), and 6,448,252 (same title, issued September 10, 2002) based on Olympia's manufacture and sale of a compounded medication containing sulfadiazine and pyrimethamine ingredients for the treatment of equine protozoal myeloencephalitis.  View the complaint here.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:


McDonnell Boehnen Hulbert & Berghoff LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.